BHC - Bausch Health Cos Inc Stock Price, Fair Value and News

8.56USD+0.03 (+0.35%)Market Closed

Market Summary

USD8.56+0.03

Market Closed

0.35%

BHC Stock Price

View Fullscreen

BHC RSI Chart

BHC Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-5.27

Price/Sales (Trailing)

0.36

EV/EBITDA

10.95

Price/Free Cashflow

3.82

BHC Price/Sales (Trailing)

BHC Profitability

EBT Margin

-4.45%

Return on Equity

721.95%

Return on Assets

-2.16%

Free Cashflow Yield

26.21%

BHC Fundamentals

BHC Revenue

Revenue (TTM)

8.8B

Rev. Growth (Yr)

9.8%

Rev. Growth (Qtr)

7.6%

BHC Earnings

Earnings (TTM)

-592.0M

Earnings Growth (Yr)

90.49%

Earnings Growth (Qtr)

89.68%

Breaking Down BHC Revenue

Last 7 days

-2.4%

Last 30 days

-10.8%

Last 90 days

6.1%

Trailing 12 Months

12.8%

How does BHC drawdown profile look like?

BHC Financial Health

Current Ratio

1.3

Debt/Equity

-267.54

Debt/Cashflow

0.05

BHC Investor Care

Dividend Yield

15.04%

Dividend/Share (TTM)

1.28

Shares Dilution (1Y)

0.93%

Diluted EPS (TTM)

-1.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.2B	8.3B	8.5B	8.8B
2022	8.3B	8.2B	8.1B	8.1B
2021	8.0B	8.5B	8.5B	8.4B
2020	8.6B	8.1B	8.0B	8.0B
2019	8.4B	8.4B	8.5B	8.6B
2018	8.6B	8.5B	8.4B	8.4B
2017	9.4B	9.2B	9.0B	8.7B
2016	10.6B	10.3B	10.0B	9.7B
2015	8.5B	9.2B	9.9B	10.4B
2014	6.6B	7.5B	8.0B	8.2B
2013	3.7B	4.0B	4.6B	5.8B
2012	2.7B	2.9B	3.2B	3.5B
2011	1.5B	1.9B	2.3B	2.4B
2010	866.7M	912.0M	907.7M	1.2B
2009	0	778.3M	799.3M	820.4M
2008	0	0	0	757.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bausch Health Cos Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	robertson russel c	acquired	31,246	10.61	2,945	-
Mar 29, 2024	wechsler amy b	acquired	6,864	10.61	647	-
Mar 29, 2024	paulson john	acquired	62,492	10.61	5,890	-
Mar 29, 2024	icahn brett	acquired	33,124	10.61	3,122	-
Mar 04, 2024	carson seana	sold	-61,867	9.8	-6,313	evp, general counsel
Mar 01, 2024	appio thomas	sold (taxes)	-1,156,950	9.89	-116,982	chief executive officer
Mar 01, 2024	carson seana	sold (taxes)	-239,763	9.89	-24,243	evp, general counsel
Mar 01, 2024	barresi john s	sold (taxes)	-31,529	9.89	-3,188	svp, controller & cao
Feb 29, 2024	carson seana	acquired	-	-	147,536	evp, general counsel
Feb 29, 2024	barresi john s	acquired	-	-	39,126	svp, controller & cao

Which funds bought or sold BHC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	4,276	20,530	-%
Apr 23, 2024	Sugarloaf Wealth Management, LLC	new	-	435	435	-%
Apr 23, 2024	MELFA WEALTH MANAGEMENT, INC.	new	-	148,540	148,540	0.11%
Apr 23, 2024	BFSG, LLC	unchanged	-	20,220	82,833	0.01%
Apr 23, 2024	WETZEL INVESTMENT ADVISORS, INC.	sold off	-100	-	-	-%
Apr 23, 2024	WASHINGTON TRUST Co	unchanged	-	3,219	13,188	-%
Apr 23, 2024	GODSEY & GIBB, INC	unchanged	-	505	2,069	-%
Apr 22, 2024	Oakworth Capital, Inc.	unchanged	-	22,927	93,920	0.01%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	1.61	109,103	426,013	-%
Apr 22, 2024	Rockwood Wealth Management, LLC	unchanged	-	34,926	143,076	0.02%

Are Funds Buying or Selling BHC?

Are funds buying BHC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BHC

No. of Funds

Unveiling Bausch Health Cos Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	goldentree asset management lp	7.6%	27,644,959	SC 13G/A
Feb 07, 2024	icahn carl c	3.95%	14,423,595	SC 13D/A
Feb 14, 2023	nomura holdings inc	3.6%	13,030,352	SC 13G/A
Feb 13, 2023	goldentree asset management lp	5.4%	19,421,054	SC 13G
May 13, 2022	va partners i, llc	4.0%	14,430,901	SC 13D/A
Feb 14, 2022	nomura holdings inc	5.4%	19,515,079	SC 13G
Dec 13, 2021	glenview capital management, llc	4.75%	17,078,657	SC 13D/A
Jun 21, 2021	va partners i, llc	5.0%	17,941,603	SC 13D/A
Apr 23, 2021	meruelo alex	5.51%	19,604,777	SC 13G
Mar 16, 2021	icahn carl c	3.98%	14,169,189	SC 13D/A

Recent SEC filings of Bausch Health Cos Inc

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	DEFA14A	DEFA14A
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	ARS	ARS
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Bausch Health Cos Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.2B	-3.67%	-8.64%	10.18	4.2	6.46%	95.94%
MRK	321.7B	60.1B	2.46%	9.45%	881.36	5.35	1.40%	-97.49%
PFE	148.3B	46.5B	-3.80%	-34.05%	-106.79	3.19	42.59%	-114.62%
AMGN	146.3B	28.2B	-0.95%	11.90%	21.78	5.19	7.09%	2.52%
GILD	83.6B	27.1B	-7.68%	-22.69%	14.75	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-6.26%	55.93%	-25.32	0.92	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-2.65%	-15.52%	-325.34	0.89	4.58%	90.97%
ALKS	4.1B	1.7B	-11.07%	-16.83%	11.39	2.44	49.61%	324.78%
BHC	3.1B	8.8B	-10.77%	12.83%	-5.27	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.43%	-0.05%	14.31	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-20.35%	-21.70%	-4.05	1.92	24.65%	80.36%
TXMD	22.3M	1.3M	-17.90%	-49.19%	-2.17	17.09	-98.14%	-109.18%
ACRX	16.3M	-	-14.29%	38.83%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-32.73%	-94.43%	-0.18	0.13	80.00%	43.08%
ACOR	645.9K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Bausch Health Cos Inc News

Latest updates

Bausch Health Cos Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	7.6%	2,408,000,000	2,238,000,000	2,167,000,000	1,944,000,000	2,193,000,000	2,046,000,000	1,967,000,000	1,918,000,000	2,196,000,000	2,111,000,000	2,100,000,000	2,027,000,000	2,213,000,000	2,138,000,000	1,664,000,000	2,012,000,000	2,224,000,000	2,209,000,000	2,152,000,000	2,016,000,000	2,121,000,000
Costs and Expenses	-8.0%	2,046,000,000	2,224,000,000	1,755,000,000	1,769,000,000	2,429,000,000	1,802,000,000	1,806,000,000	1,633,000,000	1,829,000,000	1,537,000,000	2,370,000,000	2,248,000,000	2,218,000,000	1,678,000,000	1,691,000,000	1,764,000,000	3,300,000,000	1,880,000,000	1,895,000,000	1,729,000,000	2,096,000,000
S&GA Expenses	7.1%	766,000,000	715,000,000	711,000,000	725,000,000	666,000,000	661,000,000	676,000,000	622,000,000	680,000,000	653,000,000	685,000,000	606,000,000	636,000,000	572,000,000	526,000,000	633,000,000	668,000,000	648,000,000	651,000,000	587,000,000	626,000,000
EBITDA Margin	17.6%	0.25	0.21	0.32	0.32	0.34	0.39	0.36	0.29	0.23	0.19	0.19	0.24	-	-	-	-	-	-	-	-	-
Interest Expenses	7.1%	363,000,000	339,000,000	319,000,000	307,000,000	307,000,000	385,000,000	410,000,000	362,000,000	343,000,000	351,000,000	364,000,000	368,000,000	379,000,000	374,000,000	385,000,000	396,000,000	391,000,000	406,000,000	409,000,000	406,000,000	-
Income Taxes	-28.6%	40,000,000	56,000,000	52,000,000	73,000,000	53,000,000	36,000,000	10,000,000	-16,000,000	-51,000,000	25,000,000	-77,000,000	16,000,000	-242,000,000	5,000,000	-112,000,000	-26,000,000	47,000,000	-18,000,000	-9,000,000	-74,000,000	-84,000,000
Earnings Before Taxes	97.9%	-7,000,000	-326,000,000	79,000,000	-136,000,000	-357,000,000	439,000,000	-129,000,000	-82,000,000	21,000,000	216,000,000	-670,000,000	-591,000,000	-394,000,000	75,000,000	-437,000,000	-178,000,000	-1,470,000,000	-66,000,000	-179,000,000	-122,000,000	-426,000,000
EBT Margin	48.6%	-0.04	-0.09	0.00	-0.02	-0.02	0.03	0.00	-0.06	-0.12	-0.17	-0.19	-0.17	-	-	-	-	-	-	-	-	-
Net Income	89.7%	-39,000,000	-378,000,000	26,000,000	-201,000,000	-410,000,000	399,000,000	-145,000,000	-69,000,000	69,000,000	188,000,000	-595,000,000	-610,000,000	-153,000,000	71,000,000	-326,000,000	-152,000,000	-1,516,000,000	-49,000,000	-171,000,000	-52,000,000	-344,000,000
Net Income Margin	40.0%	-0.07	-0.11	-0.02	-0.04	-0.03	0.03	0.01	-0.05	-0.11	-0.14	-0.15	-0.13	-	-	-	-	-	-	-	-	-
Free Cashflow	21.7%	292,000,000	240,000,000	178,000,000	107,000,000	409,000,000	-1,317,000,000	71,000,000	-109,000,000	-54,000,000	501,000,000	333,000,000	377,000,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.1%	27,350	27,064	25,503	25,445	25,686	26,298	28,171	29,090	29,202	29,252	30,042	30,197	31,199	31,562	31,396	32,630	33,863	31,667	32,354	32,551	32,492
Current Assets	10.9%	5,596	5,048	4,461	4,237	4,247	4,010	5,417	5,836	5,607	5,324	5,450	5,392	5,342	5,671	5,278	5,504	6,969	4,305	4,467	4,275	4,211
Cash Equivalents	24.6%	947	760	579	518	564	486	659	1,249	582	690	642	679	1,816	977	896	912	3,244	825	878	782	721
Inventory	21.4%	1,544	1,272	1,240	1,222	1,090	1,056	1,073	1,045	993	1,058	1,086	1,076	1,094	1,224	1,226	1,124	1,107	1,100	1,060	1,012	934
Net PPE	7.8%	1,707	1,584	1,599	1,596	1,600	1,507	1,545	1,579	1,598	1,584	1,590	1,556	1,567	1,550	1,496	1,450	1,466	1,390	1,372	1,341	1,353
Goodwill	48521.7%	11,183	23.00	11,628	11,579	11,547	12,044	12,266	12,427	12,457	12,477	12,527	12,485	13,044	13,160	13,084	13,034	13,126	13,052	13,160	13,121	13,142
Liabilities	0.5%	27,432	27,299	25,232	25,300	25,426	25,865	27,918	29,231	29,236	29,387	30,653	30,321	30,594	30,907	30,850	31,075	32,727	29,107	29,666	29,772	29,677
Current Liabilities	1.8%	4,302	4,224	3,967	3,923	3,941	3,831	4,997	4,774	5,198	5,437	5,517	4,898	4,913	4,732	4,718	4,886	6,248	3,735	3,705	3,941	3,836
Long Term Debt	0.2%	21,938	21,894	20,108	20,207	20,334	20,804	21,664	23,168	22,654	22,358	23,439	23,738	23,925	24,343	24,357	24,424	24,661	23,466	24,023	23,924	24,077
LT Debt, Current	-16.0%	450	536	444	446	432	411	150	-	-	-	-	-	-	-	1.00	4.00	1,234	100	56.00	257	228
LT Debt, Non Current	0.2%	21,938	21,894	20,108	20,207	20,334	20,804	21,664	23,168	22,654	22,358	23,439	23,738	23,925	24,343	24,357	24,424	24,661	23,466	24,023	23,924	24,077
Shareholder's Equity	-Infinity%	-82.00	-	271	145	260	433	253	-	-34.00	-	-	-	605	655	546	790	1,136	2,560	2,688	2,779	2,815
Retained Earnings	-0.4%	-9,778	-9,739	-9,361	-9,387	-9,186	-8,776	-9,175	-9,030	-8,961	-9,030	-9,218	-8,623	-8,013	-7,860	-7,931	-7,605	-7,452	-5,936	-5,887	-5,716	-5,664
Additional Paid-In Capital	12.6%	214	190	188	171	159	129	104	415	462	437	413	393	454	435	411	396	429	406	384	374	413
Shares Outstanding	0.1%	365	365	364	364	362	363	362	361	359	359	358	357	-	-	-	-	-	-	-	-	-
Minority Interest	-0.5%	940	945	934	945	952	958	946	75.00	72.00	69.00	76.00	73.00	70.00	68.00	72.00	71.00	73.00	78.00	87.00	86.00	82.00
Float	-	-	-	2,419	-	-	-	2,507	-	-	-	8,714	-	-	-	5,665	-	-	-	7,881	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	38.3%	390	282	206	154	475	-1,263	123	-63.00	24.00	564	395	443	394	256	200	261	234	515	339	413	319
Share Based Compensation	0%	29.00	29.00	33.00	41.00	35.00	33.00	26.00	32.00	33.00	33.00	31.00	31.00	24.00	27.00	27.00	27.00	25.00	26.00	27.00	24.00	22.00
Cashflow From Investing	92.2%	-148	-1,889	-30.00	-78.00	-136	-53.00	-58.00	-56.00	-80.00	588	-43.00	-56.00	-84.00	-70.00	-67.00	-40.00	-85.00	-73.00	-58.00	-203	-62.00
Cashflow From Financing	-104.4%	-79.00	1,816	-120	-142	-276	-36.00	-630	468	275	-1,157	-388	-243	-503	-117	-153	-1,521	2,255	-474	-188	-150	-502

BHC Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues
Revenues	$ 8,757	$ 8,124	$ 8,434
Expenses
Selling, general and administrative	2,917	2,625	2,624
Research and development	604	529	465
Amortization of intangible assets	1,077	1,215	1,375
Goodwill impairments	493	824	469
Asset impairments, including loss on assets held for sale	54	15	234
Restructuring, integration, separation and IPO costs	62	63	50
Other expense, net	28	35	373
Total Expenses	7,794	7,670	7,984
Operating income	963	454	450
Interest income	26	14	7
Interest expense	(1,328)	(1,464)	(1,426)
Gain (loss) on extinguishment of debt	1	875	(62)
Foreign exchange and other	(52)	(8)	7
Loss before income taxes	(390)	(129)	(1,024)
(Provision for) benefit from income taxes	(221)	(83)	87
Net loss	(611)	(212)	(937)
Net loss (income) attributable to noncontrolling interest	19	(13)	(11)
Net loss attributable to Bausch Health Companies Inc.	$ (592)	$ (225)	$ (948)
Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)	$ (1.62)	$ (0.62)	$ (2.64)
Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)	$ (1.62)	$ (0.62)	$ (2.64)
Basic weighted-average common shares (in shares)	364,900	362,000	358,900
Diluted weighted-average common shares (in shares)	364,900	362,000	358,900
Product sales
Revenues
Revenues	$ 8,663	$ 8,025	$ 8,328
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	2,519	2,316	2,350
Other revenues
Revenues
Revenues	94	99	106
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 40	$ 48	$ 44

BHC Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 947	$ 564
Restricted cash and other settlement deposits	15	27
Trade receivables, net	1,998	1,790
Inventories, net	1,544	1,090
Prepaid expenses and other current assets	1,092	776
Total current assets	5,596	4,247
Property, plant and equipment, net	1,707	1,600
Intangible assets, net	6,456	5,800
Goodwill	11,183	11,547
Deferred tax assets, net	2,101	2,166
Other non-current assets	307	326
Total assets	27,350	25,686
Current liabilities:
Accounts payable	719	521
Accrued and other current liabilities	3,133	2,988
Current portion of long-term debt	450	432
Total current liabilities	4,302	3,941
Acquisition-related contingent consideration	253	208
Non-current portion of long-term debt	21,938	20,334
Deferred tax liabilities, net	163	202
Other non-current liabilities	776	741
Total liabilities	27,432	25,426
Commitments and contingencies (Notes 20 and 21)
(Deficit) Equity
Common shares, no par value, unlimited shares authorized, 365,238,917 and 361,898,846 issued and outstanding at December 31, 2023 and 2022, respectively	10,423	10,391
Additional paid-in capital	214	159
Accumulated deficit	(9,778)	(9,186)
Accumulated other comprehensive loss	(1,881)	(2,056)
Total Bausch Health Companies Inc. shareholders’ deficit	(1,022)	(692)
Noncontrolling interest	940	952
Total (deficit) equity	(82)	260
Total liabilities and (deficit) equity	$ 27,350	$ 25,686

About Bausch Health Cos Inc

Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.

CEO	Mr. Thomas J. Appio
WEBSITE	bauschhealth.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	19900

Bausch Health Cos Inc Frequently Asked Questions

What is the ticker symbol for Bausch Health Cos Inc? What does BHC stand for in stocks?

BHC is the stock ticker symbol of Bausch Health Cos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bausch Health Cos Inc (BHC)?

As of Tue Apr 23 2024, market cap of Bausch Health Cos Inc is 3.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BHC stock?

You can check BHC's fair value in chart for subscribers.

What is the fair value of BHC stock?

You can check BHC's fair value in chart for subscribers. The fair value of Bausch Health Cos Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bausch Health Cos Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BHC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bausch Health Cos Inc a good stock to buy?

The fair value guage provides a quick view whether BHC is over valued or under valued. Whether Bausch Health Cos Inc is cheap or expensive depends on the assumptions which impact Bausch Health Cos Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BHC.

What is Bausch Health Cos Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, BHC's PE ratio (Price to Earnings) is -5.27 and Price to Sales (PS) ratio is 0.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BHC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bausch Health Cos Inc's stock?

In the past 10 years, Bausch Health Cos Inc has provided -0.241 (multiply by 100 for percentage) rate of return.